Anna Schnell

Anna Schnell

Auto-generated profile, based on publicly available information

Anna Schnell

CSL Behring, CSL Biologics Research Centre, Bern, Switzerland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2021 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
IOIwona Olejniczak
Iwona Olejniczak
JRJürgen A. Ripperger
Jürgen A. Ripperger
Federica SandrelliFederica Sandrelli
Federica Sandrelli
ASAnna Schnell
Anna Schnell
LMLaureen Mansencal-Strittmatter
Laureen Mansencal-Strittmatter
Urs AlbrechtUrs Albrecht
Urs Albrecht
Light at night has strong effects on physiology and behavior of mammals. It affects mood in humans, which is exploited as light therapy, and has been shown to reset the circadian clock in the suprachiasmatic nuclei (SCN). This resetting is paramount to align physiological and biochemical timing to the environmental light-dark cycle. Here we provide evidence that light at zeitgeber time (ZT) 22 affects mood-related behaviors also in mice by activating the clock gene Period1 (Per1) in the lateral habenula (LHb), a brain region known to modulate mood-related behaviors. We show that complete deletion of Per1 in mice led to depressive-like behavior and loss of the beneficial effects of light on this behavior. In contrast, specific deletion of Per1 in the region of the LHb did not affect mood-related behavior, but suppressed the beneficial effects of light. RNA sequence analysis in the mesolimbic dopaminergic system revealed profound changes of gene expression after a light pulse at ZT22. In the nucleus accumbens (NAc), sensory perception of smell and G-protein coupled receptor signaling were affected the most. Interestingly, most of these genes were not affected in Per1 knock-out animals, indicating that induction of Per1 by light serves as a filter for light-mediated gene expression in the brain. Taken together we show that light affects mood-related behavior in mice at least in part via induction of Per1 in the LHb with consequences on mood-related behavior and signaling mechanisms in the mesolimbic dopaminergic system.

25 July 2025 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
GPGabrielle Pichon
Gabrielle Pichon
CPChristelle Parent
Christelle Parent
SGStefanie Graeter
Stefanie Graeter
ASAlexander Schaub
Alexander Schaub
ASAnna Schnell
Anna Schnell
NHNathalie Heuzé-Vourc'h
Nathalie Heuzé-Vourc'h

26 March 2026 in PLOS ONE
Verified
Journal Article
Open access
MSMoritz Saxenhofer
Moritz Saxenhofer
DCDaniel Couto
Daniel Couto
SPSandra Mena Perez
Sandra Mena Perez
MIMarlies Illi
Marlies Illi
JBJustine Brodard
Justine Brodard
ASAlexander Schaub
Alexander Schaub
Heme toxicity plays a central role in the pathophysiology of Sickle Cell Disease (SCD), contributing to severe complications such as vaso-occlusion and acute chest syndrome. The continuous release of hemoglobin and heme from increased intravascular hemolysis can exceed the capacity of protective scavenger proteins, leading to heme accumulation in plasma. Interactions with various binding partners result in the formation of different plasma heme species and the compartmentalization of the plasma heme pool. In an observational biomarker study, we used novel bioanalytical assays to quantify plasma heme species in 36 stable-state SCD patients and 36 age, sex, and ethnicity-matched controls. Our results revealed substantially different compartmentalization of plasma heme, despite similar levels of total plasma heme in SCD patients (50 µmol/L) and controls (43 µmol/L). Using a correlation analysis across 85 biomarkers, we examined the association of specific heme species with SCD pathophysiology. Hemopexin-accessible heme (HAH) emerged as a refined indicator of heme burden linked to pathways driving severe SCD complications. A strong inverse correlation was observed between HAH and hemopexin (R = –0.73, p < 0.001), suggesting that hemopexin deficiency contributes to elevated HAH levels. Accurate characterization of clinically relevant plasma heme species and understanding their effects on SCD pathophysiology is essential for the development of new targeted therapies.